Comparison between late‑course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma

Lin,Qiang; Gao,Xian‑Shu; Qiao,Xue‑Ying; Liu,Chao‑Xing; Zhou,Zhi‑Guo; Guo,Zhi‑Jun; Zhao,Yan‑Nan; Chen,Kun; Asaumi,Juni‑Chi

doi:10.3892/ol.2011.287

Comparison between late‑course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma

Authors:
- Qiang Lin
- Xian‑Shu Gao
- Xue‑Ying Qiao
- Chao‑Xing Liu
- Zhi‑Guo Zhou
- Zhi‑Jun Guo
- Yan‑Nan Zhao
- Kun Chen
- Juni‑Chi Asaumi
View Affiliations

Affiliations: Department of Oncology, North China Petroleum Bureau General Hospital, Hebei 062552, P.R. China, Department of Radiation Oncology, Beijing University First Hospital, Beijing 10034, P.R. China, The First Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Hebei 050011, P.R. China, Department of Oral and Maxillofacial Radiology, Field of Tumor Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700?8525, Japan
Published online on: March 21, 2011 https://doi.org/10.3892/ol.2011.287
Pages: 557-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to compare the efficacy of late‑course accelerated hyperfractionation radiotherapy (LAFR) and concurrent chemoradiotherapy (CRT) in patients with esophageal carcinoma and to evaluate the side effects of the two treatments. A total of 22 patients with primary esophageal squamous cell carcinoma were prospectively treated with LAFR, while 25 patients, during the same period, served as the control group and received CRT. The 22 patients in the LAFR group received conventional fractionated radiotherapy of 30 Gy over a 3‑week period (5 daily fractions of 2.0 Gy per week), followed by accelerated hyperfractionated radiotherapy of 30 Gy for 2 weeks (twice daily, 1.5 Gy per fraction, with a minimal interval of 6 h between fractions, 10 fractions per week). The 25 patients in the CRT group received conventional fractionated radiotherapy of 50 Gy for 5 weeks, with 5 daily fractions of 2.0 Gy per week. Chemotherapy was started on the first day of irradiation (cisplatin 52.5 mg/m2 on Day 1 and 5‑fluorouracil 700 mg/m2 on Days 1‑5, repeated four times every 28 days). The median survival time in the LAFR and CRT groups were noted to be 17 and 21 months, respectively. The 1‑ and 2‑year overall survival rates were 63.6 and 31.6% in the LAFR group and 76 and 57.4% in the CRT group (χ2=1.670; P=0.196). The median local control in the LAFR group was 17 months, while that in the CRT group was not determined. The 1‑ and 2‑year local control rates were 54.5 and 39% in the LAFR group while those in the CRT group were 82.2 and 66.1% (χ2=3.527; P=0.060). The overall survival and local control rates of the LAFR group were lower than those of the CRT group, although the difference was not significant. The metastasis rates of the two groups were also not significantly different (χ2=0.030; P=0.862). Both acute and late adverse events in the two groups were tolerated. The side effects, including hematological toxicities, severe nausea and vomiting, and severe anorexia were significantly less in the LAFR group than those in the CRT group (P<0.05). In this small‑sample exploratory study, the overall survival and local control rates were lower with LAFR than with CRT, but the difference was not significant. Moreover, LAFR was found to have fewer side effects and be more cost‑effective compared to CRT. The long‑term effects on LAFR survival should be evaluated in a phase III clinical trial.

View Figures

View References

1	Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
2	Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
3	Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 34:615–619. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shi XH, Yao W and Liu T: Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol. 51:21–26. 1999. View Article : Google Scholar : PubMed/NCBI
5	Han C, Yang XR, Gao XS, Zhou DA and Wan J: Late course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Chin J Radiat Oncol. 8:1921999.
6	Sheng XF, Mei BD, Chai MZ, Shen XM, Gu HG and Song MZ: Late course accelerated hyperfractionation radiotherapy (LCAHR) for middle esophageal carcinoma: clinical phase III Trial. Chin J Radiat Oncol. 7:86–89. 1998.
7	Zhao KL, Shi XH, Jiang GL and Wang Y: Late-course accelerated hyperfractionation radiotherapy for localized esophageal carcinoma. Int J Radiat Oncol Biol Phys. 60:123–129. 2004. View Article : Google Scholar
8	Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
9	Lin Q, Gao XS, Qiao XY, Zhou ZG, Zhang P, Chen K, Zhao YN and Asaumi J: Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. Acta Med Okayama. 62:37–44. 2008.PubMed/NCBI
10	Gao XS, Qiao XY, Yang XR, Asaumi J, Zhou ZG, Wang YD, Zhou DA, Wan J, Kuroda M, Kishi K, Kawasaki S and Hiraki Y: Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncol Rep. 9:767–772. 2002.
11	Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000. View Article : Google Scholar : PubMed/NCBI
12	Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
13	Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:485–493. 1999.PubMed/NCBI
14	Shi XH, Wu GD and Liu XW: Comparison of treatment results between conventional fractionation and late-course accelerated fractionation for esophageal carcinoma. Chin J Radiat Oncol. 3:150–153. 1994.
15	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
16	Qiao XY, Zhou ZG, Gao XS, Ma GX and Wang J: Comparison between conventional fractionation, late-course accelerated hyperfractionation and external beam combined with intracavitary radiation in the treatment of locally moderate and advanced esophageal carcinoma. Chin J Radiat Oncol. 13:261–264. 2004.
17	Qiao XY, Gao XS, Zhou ZG, Wang X, Zhang J, Zhang P and Yang XR: Retrospective analysis on results of late-course accelerated hyperfractionation radiotherapy and conventional fractionation radiotherapy plus brachytherapy for esophageal carcinoma. Chin J Radiat Oncol. 15:182–184. 2006.
18	Ajani JA: Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 21:474–482. 1994.PubMed/NCBI
19	Zhao KL, Wang Y and Shi XH: Late course accelerated hyper-fractionated radiotherapy of upper and middle thoracic esophageal T2N0M0 carcinoma. Chin J Radiat Oncol. 24:80–82. 2002.PubMed/NCBI
20	Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP and Webb S: A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol. 61:157–163. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Han C, Li XN, Gao C, Jia JH, Cai BN, Zhang X and Xiao AQ: Short-term efficacy of intensity-modulated radiotherapy on esophageal carcinoma. Chin J Cancer. 28:1138–1142. 2009. View Article : Google Scholar : PubMed/NCBI
22	Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E and Tabernero J: Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol. 59:128–138. 2006. View Article : Google Scholar : PubMed/NCBI
23	Taira N, Doihara H, Oota T, Hara F, Shien T, Takahashi H, Yoshitomi S, Ishibe Y and Shimizu N: Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama. 60:25–34. 2006.
24	Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen MH, Moore T, Koness J, Graziano S and Wanebo HJ: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest. 19:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
25	Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M and Kelsen DP: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous- infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 22:45–52. 2004. View Article : Google Scholar
26	Ilson DH, Bains M, Kelsen DP, O’Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K and Minsky BD: Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 21:2926–2932. 2003. View Article : Google Scholar : PubMed/NCBI